Stem Cell Research

Introduction

Product Description

This report analyzes the worldwide markets for Stem Cell Research in US$ Million. Annual estimates and forecasts are provided for the period 2008 through 2017. The report provides separate comprehensive analytics for the US, Europe, and Rest of World. The report profiles 87 companies including many key and niche players such as Advanced Cell Technology, Inc., Athersys, Inc., BioE, Inc., Cellartis AB, Cryo-Cell International, Inc., Cytori Therapeutics, Inc., ES Cell International, Gamida Cell Ltd., Genzyme Corporation, International Stem Cell Corporation, Mesoblast Ltd., Neuralstem, Inc., NeuroGeneration, Inc., Osiris Therapeutics, Inc., StemCells, Inc., ThermoGenesis Corp., and ViaCord, LLC. Market data and analytics are derived from primary and secondary research. Company profiles are primarily based upon search engine sources in the public domain.

Table of Contents

Table of Contents

I. INTRODUCTION, METHODOLOGY & PRODUCT DEFINITIONS

Study Reliability and Reporting Limitations

Disclaimers

Data Interpretation & Reporting Level

• Quantitative Techniques & Analytics

Product Definitions and Scope of Study

• Types of Stem Cells
• Embryonic Stem Cells
• Adult Stem Cells

II. EXECUTIVE SUMMARY

1. MARKET OVERVIEW

• Overview
• Major Achievements Thus Far
• A Glimpse of Major Historical Events in the Area of Stem Cell Research
• New Growth Areas
• Orthopedic Products - A potential growth sector
• Utilitarian Functions of Cord Blood Stem Cells
• Umbilical Cord Stem Cells in the Treatment of Hepatic Diseases
• Human Umbilical Cord Blood-Derived Stem Cells in Insulin Synthesize
• Challenges
• Stem Cell Research And the Ethical Angle

2. MARKET DYNAMICS AND TRENDS

• North America Dominates Global Stem Cells Market
• Stem Cells Breakthrough Reshaping the Area of Medicine
• Korea Debuts the World's First Somatic Stem Cell-Based Therapy
• New Technologies Draw Significant Attention
• Ethical Issues and Nascent Stage - Key Market Restraints for Stem Cells
• Medical Tourism Picks Up in Stem Cell Therapy
• Government Regulations Fail to Prevent Medical Tourism in Stem Cell Therapy
• US and Japan Surge Ahead of Europe in Stem Cell Patents
• Table 1: Global Stem Cells Patent Analysis by Market (2010): Percentage Breakdown of Number of Patents Issued for US, Japan and Europe (includes corresponding Graph/Chart)
• Table 2: Global Stem Cells Patent Analysis by Product (2010): Percentage Breakdown of Number of Patents Issued for Adult Stem Cells, Human Embryonic Stem Cells, Mesenchymal Stem Cells, Hematopoietic Stem Cells, Neuronal Stem Cells and Others (includes corresponding Graph/Chart)
• Table 3: Leading Stem Cell Companies by Patents (2010): Percentage Breakdown of Number of Patents Secured for Geron Corp., Osiris Therapeutics, Olympus Corporation, Wisconsin Alumni Research Foundation, Kourion Therapeutics AG, Japan Science & Tech Agency and Others (includes corresponding Graph/Chart)

3. STEM CELLS MARKET DYNAMICS - BY TYPE

• Adult Stem Cells Hold Tremendous Potential
• Adult Stem Cells and Embryonic Stem Cells - A Comparison
• A Low Risk Investment
• Adult Stem Cells Garner More Investments for Research
• Low Versatility - A Major Limiting Factor for Adult Stem Cells
• Hematopoietic Stem Cells - Enjoying Enduring Success
• The Restraining Factors
• Mesenchymal Stem Cells - A Promising Therapeutic Option
• Difficulty in Isolation and Lower Understanding Hampers Growth
• Induced Pluripotent Stem Cells - An Alternative to ESCs
• A Peek Into the Discovery of iPS
• Drug Development - A Major Application for iPS
• Regenerative Medicine
• Establishing iPS Cell Banks
• Intractable and Congenital Disease Treatments
• Repairing Organs
• Embryonic Stem Cells to Transfigure the Field of Medicine
• Lack of Safety and Efficacy Data Remains A Concern

4. STEM CELLS RESEARCH BY APPLICATION

• Stem Cells in Disease Management
• Stem Cell Therapy in Regenerative Medicine
• Stem Cell Therapy - A Promising Treatment for Neurological Disorders
• Large-Scale Studies Imperative to Substantiate Early Positive Results In Cardiovascular Diseases
• Stem Cell Therapy in Cancer
• Stem Cells Set Foot in Personal Care
• Aging Population to Drive Orthopedic Stem Cell Market
• Other Diseases
• Select Key Adult Stem Cell Therapies under Development
• Stem Cells in Drug Discovery
• Tools for Drug Development

5. REGULATORY ENVIRONMENT

• Laws Governing Stem Cells Research - The Divided World
• Laws and Regulations in Stem Cells Research in Select Countries

6. PRODUCT OVERVIEW

• Stem Cell Research
• Stem Cells - Description
• Types of Stem Cells
• Embryonic Stem Cells
• mES and hES
• R-NSCs
• Adult Stem Cells
• Hematopoietic Stem Cells
• Mesenchymal Stem Cells
• Umbilical Cord Stem Cells
• Neuronal Stem Cells
• Dental Stem Cells
• Pluripotent Adult Stem Cells
• Other Key Cell Types
• The Stem Cell Line - Cell Division
• Stem Cells - Properties
• Ability to Renew on its Own
• Potency
• Definitions of Various Potencies
• Identification of Stem Cells
• Stem Cells - Applications
• History of Stem Cells
• Stem Cells - Services and Products
• Significance of Stem Cell Products/Services

7. RESEARCH BREAKTHROUGHS

• Parthenogenetic Stem Cells Holds Potential in the Treatment of Thalassemia
• hESCs - A Potential Source for Unlimited Supply of Functional Platelets
• Sperm-Producing Stem Cells For Diabetes Treatment - Researchers Explore Prospects
• Cellonis Achieves Outstanding Results of Its Stem Cell Therapy for Diabetes
• Stem Cells From Fallopian Tubes - A Prospective New Source
• Stem Cells from Fat - Enhancing Stem Cells Accessibility
• Skin Cells to Stem Cells - A New Promising Method
• Stem Cells to Repair Brain Damage After A Stroke
• ACT Shows hESCs' Potential to Become An Unlimited Source for Functional RBCs

8. PRODUCT INTRODUCTIONS/INNOVATIONS

• StemCells Launches New Antibody Reagents
• Arteriocyte Introduces Nanex Hematopoietic Stem Cell Expansion Kit
• Vitrolife Unveils Growth Factors and Cytokines for Stem Cell Cultivation
• BioTime to Introduce New Product Line of Stem Cell Products
• Chemaphor Introduces Stem Cell Regenerative Therapy
• Stempeutics Research Malaysia to Launch Ischemic CS Therapy
• Vitro Diagnostics Launches Novel Serum-free Stem Cell Growth Medium
• ThermoGenesis to Launch Res-Q System
• Invitrogen to Introduce New Technology for Safe Stem Cell Treatment
• Millipore Unveils MilliTrace(tm) Stem Cell Lines
• Millipore Unveils ESGRO Complete(tm) PLUS medium
• Bayer Launches Reformulated Liquid Leukine(r)
• Shenzhen Beike Biotechnology and CMC Launch NBPD's SCRM Industrial Project
• Vitro Unveils New Products Supporting Stem Cell Research
• Endogenous Stem Cells Activators Introduces KRONOS IV
• ArunA Biomedical and Open Biosystems Launch iPS Kit
• Invitrogen Introduces Neon Transfection Device
• Invitrogen Introduces Xenogeneic-Free Media
• NanoInk Unveils NanoStem Cell Division
• Advanced Cell Technology Unveils New Process for Functional Hepatocytes Generation

9. RECENT INDUSTRY ACTIVITY

• Sanofi-Aventis Takes Over Genzyme Corporation
• NeoStem Merges with Progenitor Cell Therapy
• EHS Enters into Joint Venture with Celulas Genetica
• RJ to Form New Subsidiary
• NuPotential and VistaGen Receive NIH Grant for Development of iPS Cells (US)
• BioCells Argentina Launches Dental Pulp Stem Cells Storage Program
• EHSI Forges Option Deal with OceanBASIS
• EHSI and Regenetech Ink License Agreement
• Transposagen Biopharmaceuticals and CDI Ink Non-exclusive License Agreement
• Kiadis Signs Licensing Agreement with Hospira to Develop and Market Hematology Product
• ACT Obtains FDA Approval for Human Clinical Trials of hESCs for Dry AMD
• OncoMed Commences Phase I Clinical Trial of OMP-59R5
• Advanced Cell Technology and Roslin Cells Ink MoU
• Mesoblast Takes Over Angioblast
• Power3 Medical Products and Rozetta-Cell Life Sciences to Merge
• University of California and BioTime Ink Material Transfer Agreement
• ISCO And John Mauldin Commence Marketing Alliance for Skincare Products
• Cord Blood America Inks Letter of Intent to Take Over Cryo-Cell Mexico
• Mesoblast Enters into Stem Cell Marketing Deal with US Company
• Bayer HealthCare Enters into Alliance with OncoMed Pharmaceuticals
• SiriCell Technologies Acquires Remaining Stake in International Stem Cell JV
• StemCells Receives Swissmedic Approval for Neural Stem Cells Trial In Chronic Spinal Cord Injury
• ACT Obtains FDA Clearance for Human Clinical Trials of hESCs for SMD
• ReNeuron Treats First Patient in Stem Cell Therapy Clinical Trial for Stroke
• Amedica/US Spine Inks a Licensing and Distribution Agreement with BioDlogics
• Vet-Stem Inks Sub-Licence Agreement with Australian Veterinary Stem Cells
• Athersys Obtains FDA Approval for Phase II Trial for IBD Using MultiStem(r)
• Stemedica and AnC Form Stem Cells JV
• Fate Therapeutics Enters into Collaboration and Licensing Agreement with BD
• BrainStorm Obtains Clearance for Stem Cell Therapy Clinical Trial for ALS in Israel
• Shrink Nanotechnologies Enters Final Stage of StemDisc Commercialization
• Cryo-Cell's License Partner S-Evans Biosciences Opens New Laboratory
• Geron Receives FDA Approval to Initiate Clinical Trials of hESCs for Treating Acute Spinal Cord Injuries
• Cytori Therapeutics' Celution System Obtains European Approval
• TGA Grants Approval to Mesoblast to Supply MPC Products
• AssureImmune and Banco Merge
• Salk Institute to Use Cyntellect's Cell Processing Workstation LEAP(tm)
• STEMCELL Inks Agreement with Stanford University for Virus Free Technique
• NeoStem Inks Partnership Agreement with Catholic Church
• Stemgent Signs Deal with Miltenyi to Co-develop and Market Stem Cell Research Products
• BioTime Acquires ES Cell International
• Cipla Enters into Partnership with Stempeutics to Enter Stem Cell Segment
• Vitro Diagnostics Signs Contract with HemoGenix
• Fate Acquires Verio Therapeutics
• Vitrolife Inks Licensing Agreement with Finn-Medi Research
• AXM Pharma to Establish Stem Cell Plant
• Stem Cell Therapy Merges with Histostem
• Cord Blood America Enters into Contract with BioE for Cord Blood Processing System
• Pfizer Acquires Rights to Athersys' Stem Cell Therapy
• Enterprise Investors Acquires Large Interest in PBKM
• Fate Therapeutics to Distribute Stem Cell Products through Becton Dickinson
• NHMC Merges with BioStem Genetics
• Riverside Acquires Crioestaminal
• Cryo-Cell International Signs Distribution Agreement with S-Evans Biosciences
• Jordanian Stem Cell Purchases Stemedica International's Stem Cell Technology
• BrainStorm Enters into Agreement with Protein Production Services
• Novartis Acquires Opexa's Stem Cell Technology
• ThermoGenesis Expands Alliance with Celling Technologies
• Bioheart to Test MyoCell SDF-1 in REGEN Trial
• Osiris Initiates Enrolment for Prochymal Phase II Clinical Trial for Type I Diabetes Treatment
• Stirling Divests Interest in Australian Stem Cell Healthcare
• iZumi Bio Merges with Pierian
• iZumi Collaborates with CiRA to Expand iPSC Technology
• Novartis Forges Research and Development Partnership Agreement with Epistem
• Healthcare of Today Acquires Regenetech
• Neuralstem and China Medical University to Co-develop Treatment for Stem Cell Stroke
• Cytori Inks Agreement with GE Healthcare for StemSource(r) Technology Commercialization
• MedCell Bioscience Merges with NovaThera
• StemCells Acquires Stem Cell Sciences
• BioSante Pharmaceuticals Merges with Cell Genesys
• Cell Therapeutics Enters into Joint Venture with Spectrum Pharmaceuticals
• Cryo-Cell International Enters into Collaboration with Cryopraxis Cryobiology
• Embryome Sciences Signs Partnership Agreement with Reproductive Genetics Institute
• ENKAM Inks Licensing Agreement with STEMCELL
• Sigma-Aldrich Inks Distribution Agreement with AlphaGenix
• ThermoGenesis and Celling Technologies Extend Collaboration
• Vivalis Enters into Collaboration with SAFC Biosciences
• ReNeuron Enters into Agreement with Angel Biotechnology Holdings
• Cellartis Signs Agreement with ReproCELL
• Cellartis and AstraZeneca Extend Collaboration
• Embryome Sciences and Millipore Sign Co-Marketing Agreement
• Cytori Enters into Partnership with GE Healthcare
• Stemgent Enters into Co-Exclusive Marketing Agreement with CellDesign
• MultiCell Technologies and Maxim Biotech Sign R&D Agreement
• GE Healthcare Collaborates with Geron Corporation
• Moraga Biotechnology Licenses BLSCs to Pharmacells
• CordLife Develops Stem Cell Therapies in India
• NsGene Receives European Patent Rights
• Pfizer to Invest in Stem Cell Research
• SCTI Commences Histostem Products Distribution Process
• Geron Secures FDA Approval for Human Trial of Embryonic Stem Cell-Based Therapy
• BioE Obtains FDA Marketing Approval for PrepaCyte-CB

10. STRATEGIC CORPORATE DEVELOPMENTS - A HISTORIC PERSPECTIVE BUILDER

• StemCells Obtains FDA Approval for Phase I Clinical Trial of HuCNS-SC(r) Cells in Treatment of PMD
• Athersys Obtains IND for Using Multistem in Treating Ischemic Stroke
• Athersys Presents Initial Dosing Data of MultiStem(r) Phase I Trial in AMI
• ACT Creates Five Lines of hESCs Without Embryo Destruction
• BioE Inks Agreement with StemSoft
• ACT's Technology Generates 140 Cell Types from hESC
• ACT Develops Process for Generating Functional Hepatocytes from hESCs
• Applied Biosystems Merges with Invitrogen
• Bennett, Coleman and Co Acquires Stake in Stem One Biologicals
• BMXP Holdings Acquires Freedom Environmental Services
• Saints Capital Completes Neuronyx Acquisition
• Intercity Acquires Exordia
• iPS and Stem Cell Merge with CDI Merge
• Biohellenika Acquires Exclusive Rights of Cytori's StemSource Cell Bank
• International Stem Cell Signs Agreement with Millipore Corporation
• ReNeuron Enters into Agreement with Angel Biotechnology
• ThermoGenesis and Celling Technologies Ink a Distribution Agreement
• BioTime and Embryome Ink a Deal with International Stem Cell
• Cryo-Cell Enters into Agreement with Saneron
• Genzyme Enters into Alliance with Osiris
• VivoMedica Enters into Collaboration with Cellartis
• Histostem Signs MOU with Stem Cell Therapy
• Vantus Inks Agreement with US Davis Center for Equine Health
• Stem Cell Sciences Enters into Agreement with Pfizer
• Sigma-Aldrich Inks Distribution Agreement with AlphaGenix
• Cellartis Signs Agreement with Pfizer
• Ortec Changes Corporate Name to Forticell Bioscience
• FDA Grants Approval to Genzyme's Mozobil
• Pfizer Inaugurates Pfizer Regenerative Medicine Research Facility
• Stem Cell Therapeutics Receives Australian Patent
• STEMCELL Technologies Secures License Rights to Geron IP
• BioTime Starts Embryonic Stem Cell Solution Facility
• Geron Successfully Transplants Pancreatic Islet-Like Clusters
• StemCells Secures US Patent
• PerkinElmer Takes Over ViaCell
• Athersys' MultiStem(r) Receives US FDA Nod for Phase I Trial in BMT Support and AMI
• BioE Teams Up with Phillips Plastics for Stem Cell Therapeutics

11. FOCUS ON SELECT GLOBAL PLAYERS

• Advanced Cell Technology, Inc. (US)
• Athersys, Inc. (US)
• BioE, Inc. (US)
• Cellartis AB (Sweden)
• Cryo-Cell International, Inc. (US)
• Cytori Therapeutics, Inc. (US)
• ES Cell International (Singapore)
• Gamida Cell Ltd. (Israel)
• Genzyme Corporation (US)
• Geron Corporation (US)
• International Stem Cell Corporation (US)
• Mesoblast Ltd. (Australia)
• Neuralstem, Inc. (US)
• NeuroGeneration, Inc. (US)
• Osiris Therapeutics, Inc. (US)
• StemCells, Inc. (US)
• ThermoGenesis Corp. (US)
• ViaCord, LLC (US)

12. GLOBAL MARKET PERSPECTIVE

• Table 4: Global Recent Past, Current & Future Analysis of Adult Stem Cell Research By Geographic Region - US, Europe and Rest of World Markets Independently Analyzed with Annual Investment Figures in US$ Million for Years 2008 through 2017 (includes corresponding Graph/Chart)
• Table 5: World 10-Year Perspective for Adult Stem Cell Research by Geographic Region - Percentage Breakdown of Annual Investments for US, Europe and Rest of World Markets for Years 2008, 2011 & 2017 (includes corresponding Graph/Chart)

III. MARKET

1. THE UNITED STATES

• A. Market Analysis
• North America - Spearheading Global Stem Cells Market
• US - The Market Leader for Stem Cell Research Worldwide
• Interest in Adult Stem Cell Research Continues
• Cosmetic Enhancements Ahead of Therapies for Diseases
• Embryonic Stem Cell Research in the US Held Back by Lack of Federal Funding
• Vacillating US Policy on Federal Funding for hESC Research
• US Revokes Ban On Federal Funding for hESC Research
• Federal Funding Remains the Key for Further Progress in the Sector
• US Court's Decree to Block Federal Funding for hESC Research to Affect Biotech Industry
• Competitive Scenario
• Table 6: Leading Players in the US Stem Cell Therapeutics Market (2007): Percentage Breakdown of Value Sales for ViaCell Inc., Cryo-Cell, Osiris Therapeutics Inc., International Stem Cell Corporation, Geron Corp., Cytori Therapeutics Inc., Athersys Inc., and Others (includes corresponding Graph/Chart)
• B. Market Analytics
• Table 7: US Recent Past, Current & Future Analysis of Adult Stem Cell Research Market Analyzed with Annual Investment Figures in US$ Million for Years 2008 through 2017 (includes corresponding Graph/Chart)

2. EUROPE

• A. Market Analysis
• The UK Policy on hESC Remains In Favor of Developing the Science
• UK Adopts Practical Approach In Addressing Moral Issues
• UK- The First Country to Allow Therapeutic Cloning
• B. Market Analytics
• Table 8: European Recent Past, Current & Future Analysis of Adult Stem Cell Research Market Analyzed with Annual Investment Figures in US$ Million for Years 2008 through 2017 (includes corresponding Graph/Chart)

3. REST OF WORLD

• A. Market Analysis
• The Rise of Asia in Stem Cells Research
• US Ban on Federal Funds for hESC Research Boosts Asian Presence
• South Korea Pacing towards Regaining Lost Glory in Stem Cell Research
• Emergence of China in the Global Stem Cell Research Space
• The Indian Stem Cell Research Market - An Overview
• B. Market Analytics
• Table 9: Rest of World Recent Past, Current & Future Analysis of Adult Stem Cell Research Market Analyzed with Annual Investment Figures in US$ Million for Years 2008 through 2017 (includes corresponding Graph/Chart)

Stem Cell Research published by Global Industry Analysts, Inc. in May 1, 2012. This report consists of Pages: 551 and the price starts from US $ 4500.

The contents of this page may be different from the latest version. Please contact us for details.